Based on the Vyne Therapeutics Inc stock forecast from 4 analysts, the average analyst target price for Vyne Therapeutics Inc is USD 5.98 over the next 12 months. Vyne Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Vyne Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Vyne Therapeutics Inc’s stock price was USD 1.56. Vyne Therapeutics Inc’s stock price has changed by -8.24% over the past week, -33.05% over the past month and -44.88% over the last year.
No recent analyst target price found for Vyne Therapeutics Inc
No recent average analyst rating found for Vyne Therapeutics Inc
Company Overview Vyne Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Read Less
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhib...Read More
Frequently Asked Questions About Vyne Therapeutics Inc (VYNE) Stock
Based on ratings from 4 analysts Vyne Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 10 buy, sell and hold ratings.
Unfortunately we do not have enough data on VYNE's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for VYNE is USD 5.98 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 5.
VYNE stock's Price/Earning ratio is 1.74.
Our analysis grades VYNE stock's Price / Earning ratio at D. This means that VYNE stock's Price/Earning ratio is above 36% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this VYNE may be fairly valued for its sector
The last closing price of VYNE's stock was USD 1.56.
The most recent market capitalization for VYNE is USD 0.04B.
Based on targets from 4 analysts, the average taret price for VYNE is projected at USD 5.98 over the next 12 months.
This means that VYNE's stock price may go up by +283.01% over the next 12 months.
We can't find any ETFs which contains Vyne Therapeutics Inc's stock.
As per our most recent records Vyne Therapeutics Inc has 0 Employees.
Vyne Therapeutics Inc's registered address is 685 Route 202/206 N, Bridgewater, NJ, United States, 08807.
You can get more information about it from Vyne Therapeutics Inc's website at https://www.vynetherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Vyne Therapeutics Inc (VYNE) Stock
Based on ratings from 4 analysts Vyne Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 10 buy, sell and hold ratings.
Unfortunately we do not have enough data on VYNE's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for VYNE is USD 5.98 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 5.
VYNE stock's Price/Earning ratio is 1.74.
Our analysis grades VYNE stock's Price / Earning ratio at D. This means that VYNE stock's Price/Earning ratio is above 36% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this VYNE may be fairly valued for its sector
The last closing price of VYNE's stock was USD 1.56.
The most recent market capitalization for VYNE is USD 0.04B.
Based on targets from 4 analysts, the average taret price for VYNE is projected at USD 5.98 over the next 12 months.
This means that VYNE's stock price may go up by +283.01% over the next 12 months.
We can't find any ETFs which contains Vyne Therapeutics Inc's stock.
As per our most recent records Vyne Therapeutics Inc has 0 Employees.
Vyne Therapeutics Inc's registered address is 685 Route 202/206 N, Bridgewater, NJ, United States, 08807.
You can get more information about it from Vyne Therapeutics Inc's website at https://www.vynetherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VYNE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
